West Pharmaceutical
310 hedge funds and large institutions have $6.36B invested in West Pharmaceutical in 2017 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 140 increasing their positions, 90 reducing their positions, and 25 closing their positions.
137% more call options, than puts
Call options by funds: $1.37M | Put options by funds: $577K
76% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 25
56% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 90
17% more capital invested
Capital invested by funds: $5.44B → $6.36B (+$921M)
5% more funds holding
Funds holding: 295 → 310 (+15)
0.61% more ownership
Funds ownership: 90.94% → 91.55% (+0.61%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RP
Riverbridge Partners
Minneapolis,
Minnesota
|
+$47M |
| 2 |
BlackRock
New York
|
+$38M |
| 3 |
Renaissance Technologies
New York
|
+$28.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.8M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$22.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$34.7M |
| 2 |
Millennium Management
New York
|
-$29.1M |
| 3 |
CRCP
Copper Rock Capital Partners
Boston,
Massachusetts
|
-$28.2M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$25.7M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$21.4M |
WST Hedge Fund Activity: Q2 2017 in Review
310 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q2 2017, worth a combined $6.36B — up 17% from $5.44B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new WST positions and 25 closed out — a net gain of 19 holders — while 140 added to existing stakes and 90 trimmed.
The largest buyer was Riverbridge Partners, opening a new position worth an estimated $47M. The largest seller was Victory Capital Management, cutting an estimated $34.7M.
- 310 institutional investors held West Pharmaceutical (WST) as of Q2 2017, up from 295 in Q1 2017.
- Funds reported $6.36B of West Pharmaceutical stock for Q2 2017, up 17% quarter-over-quarter.
- 44 funds opened new West Pharmaceutical positions in Q2 2017 and 25 closed out, a net change of +19 holders.
- The largest West Pharmaceutical buyer in Q2 2017 was Riverbridge Partners, an estimated $47M added.
- The largest West Pharmaceutical seller in Q2 2017 was Victory Capital Management, an estimated $34.7M sold.
Based on aggregated 13F filings for Q2 2017.